Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of jaketinib hydrochloride tablets in adults with moderate-to-severe atopic dermatitis
CTR20221417Phase 3Active
- Sponsor
- Zelgen
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of jaktinib in atopic dermatitis (AD), sponsored by Zelgen. Started Jul 2022; status: active.
02
Drugs
jaktinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20221417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221417.